AAPL340.86-2.08 (-0.61%) ▼|ABBV289.30+6.62 (+2.34%) ▲|ABT103.44-0.62 (-0.60%) ▼|ACN240.67+3.74 (+1.58%) ▲|ADBE255.12+8.03 (+3.25%) ▲|AMAT405.22-7.89 (-1.91%) ▼|AMD542.38+4.33 (+0.80%) ▲|AMGN433.87+8.93 (+2.10%) ▲|AMT185.39+2.36 (+1.29%) ▲|AMZN263.08+0.63 (+0.24%) ▲|AVGO335.10+0.51 (+0.15%) ▲|AXP320.55+4.14 (+1.31%) ▲|BA189.91-1.51 (-0.79%) ▼|BAC51.03+0.64 (+1.26%) ▲|BKNG163.27+0.67 (+0.41%) ▲|BLK1,135.97+11.37 (+1.01%) ▲|BMY61.36+2.53 (+4.29%) ▲|BNY144.20+1.76 (+1.24%) ▲|BRK-B538.54+6.31 (+1.18%) ▲|C122.41+0.72 (+0.59%) ▲|CAT725.81+0.02 (+0.00%) ▲|CL94.06+1.20 (+1.29%) ▲|CMCSA22.12+0.22 (+1.00%) ▲|COF201.61+1.78 (+0.89%) ▲|COP144.94-0.30 (-0.21%) ▼|COST994.24-1.30 (-0.13%) ▼|CRM239.41-3.05 (-1.26%) ▼|CSCO106.13-0.37 (-0.35%) ▼|CVS94.59+1.91 (+2.06%) ▲|CVX223.53-0.85 (-0.38%) ▼|DE635.15+8.15 (+1.30%) ▲|DHR226.43+2.00 (+0.89%) ▲|DIS111.26+1.67 (+1.52%) ▲|DUK121.12+1.85 (+1.55%) ▲|EMR159.67-0.87 (-0.54%) ▼|FDX300.27+6.49 (+2.21%) ▲|GD343.00+1.57 (+0.46%) ▲|GE297.45-13.84 (-4.44%) ▼|GEV899.53-8.91 (-0.98%) ▼|GILD155.41+2.34 (+1.53%) ▲|GM76.69-6.06 (-7.32%) ▼|GOOG337.70-2.46 (-0.72%) ▼|GOOGL341.56-2.62 (-0.76%) ▼|GS885.62+9.84 (+1.12%) ▲|HD315.71+5.83 (+1.88%) ▲|HON212.83+2.85 (+1.36%) ▲|IBM240.07+3.68 (+1.56%) ▲|INTC93.26+1.23 (+1.33%) ▲|INTU335.41+9.79 (+3.01%) ▲|ISRG436.38+3.20 (+0.74%) ▲|JNJ259.09+5.30 (+2.09%) ▲|JPM336.37+2.84 (+0.85%) ▲|KO92.97-0.45 (-0.48%) ▼|LIN498.89-4.55 (-0.90%) ▼|LLY1,296.20+55.86 (+4.50%) ▲|LMT547.25-0.98 (-0.18%) ▼|LOW198.90+2.98 (+1.52%) ▲|LRCX265.19-7.01 (-2.58%) ▼|MA622.14+5.74 (+0.93%) ▲|MCD246.17+3.50 (+1.44%) ▲|MDLZ63.91+0.57 (+0.90%) ▲|MDT94.29+1.52 (+1.64%) ▲|META690.30-15.14 (-2.15%) ▼|MMM170.09+8.08 (+4.99%) ▲|MO74.99+0.90 (+1.21%) ▲|MRK148.25+4.62 (+3.21%) ▲|MS180.62+2.15 (+1.20%) ▲|MSFT531.69-1.83 (-0.34%) ▼|MU911.34+6.44 (+0.71%) ▲|NEE79.10+0.93 (+1.18%) ▲|NFLX69.71-0.15 (-0.21%) ▼|NKE37.78+0.57 (+1.53%) ▲|NOW148.42+3.06 (+2.11%) ▲|NVDA217.03-0.06 (-0.03%) ▼|ORCL132.33+2.74 (+2.11%) ▲|PEP134.05+0.48 (+0.36%) ▲|PFE30.13+0.69 (+2.34%) ▲|PG158.51+0.82 (+0.52%) ▲|PLTR194.61+0.46 (+0.24%) ▲|PM201.31+0.26 (+0.13%) ▲|QCOM175.35+1.82 (+1.05%) ▲|RTX190.27-1.84 (-0.96%) ▼|SBUX99.54+1.67 (+1.71%) ▲|SCHW90.78+1.20 (+1.34%) ▲|SO90.75+1.48 (+1.66%) ▲|SPG205.75+3.26 (+1.61%) ▲|T23.51+0.31 (+1.31%) ▲|TMO687.69+8.31 (+1.22%) ▲|TMUS158.51+2.42 (+1.55%) ▲|TSLA373.79+5.73 (+1.56%) ▲|TXN279.73+3.58 (+1.30%) ▲|UBER68.69-1.27 (-1.82%) ▼|UNH421.26+14.38 (+3.53%) ▲|UNP287.20+0.19 (+0.06%) ▲|UPS98.73+1.27 (+1.30%) ▲|USB58.83+0.98 (+1.69%) ▲|V407.05+4.13 (+1.03%) ▲|VZ44.52+0.37 (+0.84%) ▲|WFC81.91+0.11 (+0.13%) ▲|WMT118.18-0.52 (-0.44%) ▼|XOM176.57-1.71 (-0.96%) ▼|AAPL340.86-2.08 (-0.61%) ▼|ABBV289.30+6.62 (+2.34%) ▲|ABT103.44-0.62 (-0.60%) ▼|ACN240.67+3.74 (+1.58%) ▲|ADBE255.12+8.03 (+3.25%) ▲|AMAT405.22-7.89 (-1.91%) ▼|AMD542.38+4.33 (+0.80%) ▲|AMGN433.87+8.93 (+2.10%) ▲|AMT185.39+2.36 (+1.29%) ▲|AMZN263.08+0.63 (+0.24%) ▲|AVGO335.10+0.51 (+0.15%) ▲|AXP320.55+4.14 (+1.31%) ▲|BA189.91-1.51 (-0.79%) ▼|BAC51.03+0.64 (+1.26%) ▲|BKNG163.27+0.67 (+0.41%) ▲|BLK1,135.97+11.37 (+1.01%) ▲|BMY61.36+2.53 (+4.29%) ▲|BNY144.20+1.76 (+1.24%) ▲|BRK-B538.54+6.31 (+1.18%) ▲|C122.41+0.72 (+0.59%) ▲|CAT725.81+0.02 (+0.00%) ▲|CL94.06+1.20 (+1.29%) ▲|CMCSA22.12+0.22 (+1.00%) ▲|COF201.61+1.78 (+0.89%) ▲|COP144.94-0.30 (-0.21%) ▼|COST994.24-1.30 (-0.13%) ▼|CRM239.41-3.05 (-1.26%) ▼|CSCO106.13-0.37 (-0.35%) ▼|CVS94.59+1.91 (+2.06%) ▲|CVX223.53-0.85 (-0.38%) ▼|DE635.15+8.15 (+1.30%) ▲|DHR226.43+2.00 (+0.89%) ▲|DIS111.26+1.67 (+1.52%) ▲|DUK121.12+1.85 (+1.55%) ▲|EMR159.67-0.87 (-0.54%) ▼|FDX300.27+6.49 (+2.21%) ▲|GD343.00+1.57 (+0.46%) ▲|GE297.45-13.84 (-4.44%) ▼|GEV899.53-8.91 (-0.98%) ▼|GILD155.41+2.34 (+1.53%) ▲|GM76.69-6.06 (-7.32%) ▼|GOOG337.70-2.46 (-0.72%) ▼|GOOGL341.56-2.62 (-0.76%) ▼|GS885.62+9.84 (+1.12%) ▲|HD315.71+5.83 (+1.88%) ▲|HON212.83+2.85 (+1.36%) ▲|IBM240.07+3.68 (+1.56%) ▲|INTC93.26+1.23 (+1.33%) ▲|INTU335.41+9.79 (+3.01%) ▲|ISRG436.38+3.20 (+0.74%) ▲|JNJ259.09+5.30 (+2.09%) ▲|JPM336.37+2.84 (+0.85%) ▲|KO92.97-0.45 (-0.48%) ▼|LIN498.89-4.55 (-0.90%) ▼|LLY1,296.20+55.86 (+4.50%) ▲|LMT547.25-0.98 (-0.18%) ▼|LOW198.90+2.98 (+1.52%) ▲|LRCX265.19-7.01 (-2.58%) ▼|MA622.14+5.74 (+0.93%) ▲|MCD246.17+3.50 (+1.44%) ▲|MDLZ63.91+0.57 (+0.90%) ▲|MDT94.29+1.52 (+1.64%) ▲|META690.30-15.14 (-2.15%) ▼|MMM170.09+8.08 (+4.99%) ▲|MO74.99+0.90 (+1.21%) ▲|MRK148.25+4.62 (+3.21%) ▲|MS180.62+2.15 (+1.20%) ▲|MSFT531.69-1.83 (-0.34%) ▼|MU911.34+6.44 (+0.71%) ▲|NEE79.10+0.93 (+1.18%) ▲|NFLX69.71-0.15 (-0.21%) ▼|NKE37.78+0.57 (+1.53%) ▲|NOW148.42+3.06 (+2.11%) ▲|NVDA217.03-0.06 (-0.03%) ▼|ORCL132.33+2.74 (+2.11%) ▲|PEP134.05+0.48 (+0.36%) ▲|PFE30.13+0.69 (+2.34%) ▲|PG158.51+0.82 (+0.52%) ▲|PLTR194.61+0.46 (+0.24%) ▲|PM201.31+0.26 (+0.13%) ▲|QCOM175.35+1.82 (+1.05%) ▲|RTX190.27-1.84 (-0.96%) ▼|SBUX99.54+1.67 (+1.71%) ▲|SCHW90.78+1.20 (+1.34%) ▲|SO90.75+1.48 (+1.66%) ▲|SPG205.75+3.26 (+1.61%) ▲|T23.51+0.31 (+1.31%) ▲|TMO687.69+8.31 (+1.22%) ▲|TMUS158.51+2.42 (+1.55%) ▲|TSLA373.79+5.73 (+1.56%) ▲|TXN279.73+3.58 (+1.30%) ▲|UBER68.69-1.27 (-1.82%) ▼|UNH421.26+14.38 (+3.53%) ▲|UNP287.20+0.19 (+0.06%) ▲|UPS98.73+1.27 (+1.30%) ▲|USB58.83+0.98 (+1.69%) ▲|V407.05+4.13 (+1.03%) ▲|VZ44.52+0.37 (+0.84%) ▲|WFC81.91+0.11 (+0.13%) ▲|WMT118.18-0.52 (-0.44%) ▼|XOM176.57-1.71 (-0.96%) ▼|
17.9 C
New York
Tuesday, October 20, 2026

Tag: treatment

newsFORsourcecompanycontentinformation1releasesmarket

Whole Genome Sequencing Market to Reach New Heights by 2030

"With cutting-edge advances in next-generation sequencing and growing interest in personalized medicine, whole genome sequencing is set to transform disease diagnosis and treatment, driving...

Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT – Advancing Breakthrough Therapy for Chronic Lower Back Pain

PHOENIX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company focused on regenerative and immune cellular therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead investigational therapy, CELZ-201-DDT, for the treatment of degenerative disc disease (DDD), a major cause of chronic lower back pain and disability.

LiqTech International Announces Second Quarter 2025 Financial Results

BALLERUP, Denmark, Aug. 13, 2025 (GLOBE NEWSWIRE) -- LiqTech International, Inc. (Nasdaq: LIQT) ("LiqTech"), a clean technology company that manufactures and markets highly specialized filtration technologies, today announced its financial results for the second quarter of 2025 for the period ended June 30, 2025.

On World Organ Donation Day KFSHRC Announces 10 Kidney Exchange Transplants Completed in 48 Hours

RIYADH, Saudi Arabia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSHRC) successfully performed 10 kidney exchange transplants over two consecutive days, setting a global record for the highest number of such procedures conducted within a two-day span at a single center, coinciding with World Organ Donation Day on August 13. This milestone reinforces KFSHRC’s position as a global leader in organ transplantation.

Mesa Air Group Reports Third Quarter Fiscal 2025 Results and Provides Update on Proposed Merger with Republic Airways Holdings Inc.

Management to Hold Call Following Market Close Today 
Management to Hold Call Following Market Close Today

i-80 Gold Reports Second Quarter 2025 Results and Project Development Highlights

RENO, Nev., Aug. 13, 2025 /CNW/ - i-80 GOLD CORP. (TSX: IAU) (NYSE American: IAUX) ("i-80 Gold", or the "Company") reports its operating and financial...

i-80 Gold Reports Second Quarter 2025 Results and Project Development Highlights

RENO, Nev., Aug. 13, 2025 /PRNewswire/ - i-80 GOLD CORP. (TSX: IAU) (NYSE American: IAUX) ("i-80 Gold", or the "Company") reports its operating and financial...

Rogue Recovery Announces Grand Opening in Grants Pass, Offering Vital Support for Rural Communities Struggling To Address Addiction Rates

GRANTS PASS, Ore., Aug. 13, 2025 /PRNewswire/ -- Rogue Recovery, a recovery community organization (RCO) dedicated to providing comprehensive peer-based support, resources, and mentoring...

Telitacicept Meets Primary Endpoint in Phase III Trial for Primary Sjögren’s Syndrome in China

YANTAI, China, Aug. 13, 2025 /PRNewswire/ -- On August 13th, Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, Telitacicept, met...

Navamedic ASA: National approvals of Flexilev® in OraFID® granted across all Nordic countries

OSLO, Norway, Aug. 13, 2025 /PRNewswire/ -- Navamedic is pleased to announce that it has received final approval for the packaging material in national...

Daewoong Therapeutics Microneedle Patch Achieves Best-in-Class Bioavailability, Proving the Strength of Its Drug-Delivery Platform

More than 80% relative bioavailability compared with injectable obesity therapy, well above the roughly 30% reported for existing microneedle patches and setting a new...

Greywolf Therapeutics begins dosing of the first treatment to target the antigenic source of autoimmunity

Greywolf starts first trial of GRWD0715, aiming for a functional cure for autoimmunity by targeting its antigenic source.

Santhera Secures Agreement with GEN for the Distribution of AGAMREE® (Vamorolone) in Türkiye

Pratteln, Switzerland, 13 August, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Gen İlaç ve Sağlık Ürünleri San. ve Tic. A.Ş. (GEN) for the distribution and promotion of AGAMREE® (vamorolone) in Türkiye for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older.

HopeAI Joins Mayo Clinic Platform to Transform the Future of Drug Development with AI

NEW YORK, Aug. 12, 2025 /PRNewswire/ -- HopeAI, an emerging leader in applying artificial intelligence (AI) to accelerate new drug development, has officially joined...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTreatment

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers